{
    "clinical_study": {
        "@rank": "94062", 
        "arm_group": [
            {
                "arm_group_label": "IDegAsp 30", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDegAsp 45", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "insulin degludec (B)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "insulin degludec (E)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of this trial is to assess the safety,\n      pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the\n      effect of the investigated drug on the body) of two insulin degludec/insulin aspart\n      (IDegAsp) preparations and two insulin degludec (insulin 454) preparations in healthy\n      Japanese male subjects. IDegAsp 45 (B) and insulin degludec (B) are explorative\n      formulations, not similar to the proposed commercial formulations."
        }, 
        "brief_title": "Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects", 
        "completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Japanese male subjects\n\n          -  Body mass index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive)\n\n          -  Body weight above or equal to 50 kg\n\n        Exclusion Criteria:\n\n          -  The receipt of any investigational drug within 16 weeks prior to this trial (the\n             planned first dosing)\n\n          -  Any clinical laboratory values deviated from the reference range at the laboratory\n             (except for cases within physiological change) or any abnormal electrocardiogram\n             (ECG) findings at the screening, as judged by the investigator or sub-investigator\n\n          -  Known or suspected allergy to trial product(s) or related products"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868555", 
            "org_study_id": "NN5401-1790"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "insulin degludec (B)", 
                    "insulin degludec (E)"
                ], 
                "description": "Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp 30", 
                "description": "Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days", 
                "intervention_name": "insulin degludec/insulin aspart 30", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp 45", 
                "description": "Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days", 
                "intervention_name": "insulin degludec/insulin aspart 45", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IDegAsp 30", 
                    "IDegAsp 45", 
                    "insulin degludec (B)", 
                    "insulin degludec (E)"
                ], 
                "description": "Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "103"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomised, Double-blind, Single Centre, Placebocontrolled, Parallel Group, Multiple s.c. Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Two SIAC Preparations and Two Insulin 454 (SIBA) Preparations in Healthy Japanese Male Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hanne Haahr", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "Day 1-6 and 7-28 days after day 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868555"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum insulin 454 concentration curve", 
                "safety_issue": "No", 
                "time_frame": "0-96 hours after last dosing"
            }, 
            {
                "measure": "Area under the serum insulin aspart concentration curve", 
                "safety_issue": "No", 
                "time_frame": "0-6 hours after dosing"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}